BTIG analyst Yun Zhong downgraded Magenta Therapeutics to Neutral from Buy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MGTA:
- Wedbush downgrades Magenta Therapeutics to Neutral, lowers target to $1
- Magenta Therapeutics downgraded to Neutral from Outperform at Wedbush
- Magenta Therapeutics pauses MGTA-117 trial following Grade 5 SAE
- Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
- Magenta Therapeutics price target lowered to $3 from $6 at BTIG